BMY (Bristol Myers Squibb) Stock Analysis - AI Report

Bristol Myers Squibb (BMY) is a publicly traded Healthcare sector company. As of May 20, 2026, BMY trades at $58.52 with a market cap of $117.03B and a P/E ratio of 16.83. BMY moved +0.20% today. Year to date, BMY is +9.07%; over the trailing twelve months it is +23.49%. Its 52-week range spans $42.52 to $63.33. Analyst consensus is buy with an average price target of $64.29. Rallies surfaces BMY's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What is the AI research view on BMY?

Rallies AI research for BMY combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.

BMY Key Metrics

Key financial metrics for BMY
MetricValue
Price$58.52
Market Cap$117.03B
P/E Ratio16.83
EPS$3.47
Dividend Yield0.63%
52-Week High$63.33
52-Week Low$42.52
Volume5.21M
Avg Volume0
Revenue (TTM)$48.19B
Net Income$7.05B
Gross Margin71.08%

Latest BMY News

Recent BMY Insider Trades

  • Elkins David V sold 25.52K (~$1.57M) on Apr 1, 2026.
  • Elkins David V sold 4.48K (~$278.05K) on Apr 1, 2026.

BMY Analyst Consensus

18 analysts cover BMY: 0 strong buy, 6 buy, 12 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $64.29.

Common questions about BMY

What is the AI research view on BMY?
Rallies AI research for BMY combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
What data powers the Rallies AI report for BMY?
Rallies AI research for BMY combines live market data, financials, news, analyst context, hedge fund ownership, politician disclosures, insider activity, and risk factors.
Is BMY research on Rallies investment advice?
No. Rallies provides research, data, and educational context for BMY. It does not provide personalized investment advice.
BMY

Bristol Myers Squibb